• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·ALIF-B.ST
Share

AddLife AB Stocks

SEK 160.1Last Updated 12.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

SEK 1.95B

SEK 160.1
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and research organizations (such as colleges and universities), and key players within the food and pharmaceutical industries. The firm's operations are divided into two distinct divisions: Labtech and Medtech. The Labtech segment provides a comprehensive array of products, integrated solutions, and expert services, focusing on diagnostics, biomedical research, and general laboratory requirements. This encompasses specialized instruments for areas like haematology, pathology, immediate diagnostic testing (point-of-care), cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, along with consumables and advanced analytical machinery. This division further offers vital support, maintenance, consultancy, and educational programs. Conversely, the Medtech segment concentrates on supplying a wide range of medical devices tailored for critical applications such as surgical procedures, respiratory support, intensive care, wound management, and enteral nutrition. It also develops products for fall prevention, welfare technology, and ear, nose, and throat conditions, in addition to offering specific assistive devices for bathrooms and specialized aids for children with disabilities. AddLife maintains a broad international presence, conducting business in its home country of Sweden, across the Nordics (Finland, Denmark, Norway), the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, other parts of Europe, and globally.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of ALIF-B.ST is 202 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026